Figure 5
Heterogeneity FLIRR response upon treatment with anti-cancer drug doxorubicin in AA PCa (Control, 15, 30, 45, 60 min). Segmented cells were analyzed as described in Fig. 1. To reduce the complexity, cell data was sorted by their response to treatment (low, medium, high), measured by FLIRR, then merged within the three responder categories. (A–C) Responder categories by time point for mitochondrial morphology data, (D–F) responder categories by time point for whole-cell (without nucleus) data. (G,H) Median response vs. untreated control by time point for each of the responder categories. (I) Images represent the continuing effects of doxorubicin on increasing FLIRR before the onset of apoptosis28.
